<DOC>
	<DOCNO>NCT03059251</DOCNO>
	<brief_summary>This observational study aim study effectiveness safety Obinutuzumab common clinical practice setting Argentina . The study population comprise patient chronic lymphocytic leukemia ( CLL ) receive indication treatment Obinutuzumab per routine clinical practice .</brief_summary>
	<brief_title>Observational Study : Safety Effectiveness Obinutuzumab Chronic Lymphocytic Leukemia Argentina</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<criteria>Have receive least one dose Obinutuzumab per local label clinical practice . Included clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>CLL , obinutuzumab , treatment</keyword>
</DOC>